Merck to collaborate with GenScript to accelerate cell and gene therapy industrialization in China

MerckMerck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.

"Manufacturing of high-quality plasmid and viral vectors is one of the most critical components in the commercialization of cell and gene therapy," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "As we are one of the world’s largest manufacturers of viral vectors, this collaboration will give GenScript access to our leading experience of nearly three decades in gene and cell therapy manufacturing."

"We are excited about the planned collaboration with Merck to better serve our local and overseas customers with cGMP manufacturing facilities, and to accelerate the drug commercialization process," said Daniel Wang Dongliang, vice president of Operations, Biologics Department, at GenScript.

The parties envision an alliance that will accelerate the industrialization and commercialization of cell and gene therapy in China. GenScript, a leading biotech company headquartered in Nanjing, China, aims to create a global-standard platform of plasmid and virus manufacturing service in the country. Merck plans to provide GenScript with comprehensive products, training and consulting services covering process design, facility concept design and quality management system set-up from lab development to large-scale GMP manufacturing.

Merck is among only a few manufacturers that have an industrialized process to make viral vectors. To create personalized therapy products, genes are delivered into immune cells using viral vectors, such as the ones that Merck produces. The company offers a unique combination as a contract manufacturing organization and as a bioprocess manufacturing equipment maker.

A confluence of demand, growth and subsequent need to scale the cell and gene therapy market in China is an important driver for Merck to deliver its expertise to this region. According to clinicaltrials.gov, China is the world-leader in terms of where gene-modified cell therapy clinical trials are conducted. Today, more than 130 companies in China are developing cell and gene therapies ranging from chimeric antigen receptor T cell therapy (CAR-T) / T cell receptor therapy (TCR-T) and adeno-associated virus (AAV) to oncolytic virus(1). Moreover, 28 cell and gene therapy Investigational New Drug applications(2) were submitted in China between Dec. 2017 - Dec. 2018 with more than a third already approved for clinical trials.

Merck plans to provide a complete set of process products, services and staff training to support GenScript in building a world-class plasmid and viral vector manufacture platform to accelerate the industrialization of cell and gene therapy in China.

About GenScript

GenScript Biotech Corp. is a world leader in the biological reagent service industry. Headquartered in Nanjing, China, the Group currently has a couple of R&D, production and operation centers in Nanjing and New Jersey, two production bases in Zhenjiang and Jinan, two European bases for its subsidiary Legend in Netherlands and Ireland, and a wholly-owned subsidiary in Japan.

With the fast growth in developing biological reagents, the Company now expands its business into immunotherapy, contract development and manufacturing organization (CDMO), lab equipment and industrial microbiology applications. To support these businesses, it has established open and innovation-driven technological platforms, GMP facilities for pre-clinical drug discovery and pharmaceutical product development and a full-range industrial microbial R&D and industrialization platform for enzyme screening, GMP plasmid and virus production, antibody drug discovery (Bispecific antibodies technology; Hybridoma technology; Humanized Antibody technology; Phage display technology), genetic engineering, protein engineering and fermentation process optimization. The Company is uniquely positioned and well equipped to further fulfill its mission in making people and nature healthier through biotechnology.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene- editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - Merck is everywhere. In 2018, Merck generated sales of €14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

1. HSmap report 2017 - Chinese Gene Therapy Industry Atlas
2. Source: Yaozhi database

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...

Sports playbook helps doctors predict cancer patie…

In this season of global soccer competitions and hotly contested political primaries, bookies and pundits are scouring every evolving scrap of information and sifting thr...

FDA seeks public feedback on new drug approval tra…

Today the U.S. Food and Drug Administration issued a Federal Register notice, New Drugs Regulatory Program Modernization: Improving Approval Package Documentation, to ope...